Shefali Agarwal
Chief Executive Officer at VALERIO THERAPEUTICS
Net worth: 40 596 $ as of 30/04/2024
Shefali Agarwal active positions
| Companies | Position | Start | End |
|---|---|---|---|
| FATE THERAPEUTICS, INC. | Director/Board Member | 15/07/2019 | - |
| Independent Dir/Board Member | 15/07/2019 | - | |
| GRITSTONE BIO, INC. | Director/Board Member | 01/06/2021 | - |
| Independent Dir/Board Member | 01/06/2021 | - | |
| VALERIO THERAPEUTICS | Chairman | 29/07/2021 | - |
| Chief Executive Officer | 06/04/2022 | - | |
| President | 06/04/2022 | - | |
| Director/Board Member | 01/06/2021 | 29/07/2021 | |
| Independent Dir/Board Member | 01/06/2021 | 29/07/2021 |
Career history of Shefali Agarwal
Former positions of Shefali Agarwal
| Companies | Position | Start | End |
|---|---|---|---|
| EPIZYME, INC. | Chief Tech/Sci/R&D Officer | 01/06/2018 | 06/04/2022 |
| SQZ BIOTECHNOLOGIES COMPANY | Chief Tech/Sci/R&D Officer | 01/07/2017 | 01/05/2018 |
Training of Shefali Agarwal
| Karnataka University | Doctorate Degree |
| The Johns Hopkins University | Graduate Degree |
| Merrick School of Business | Graduate Degree |
Statistics
International
| United States | 7 |
| India | 2 |
| France | 2 |
Operational
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| Private companies | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Shefali Agarwal
- Experience